Scientists have embarked on a thrilling molecular detective story to uncover the mysterious relationship between plasma levels of tissue-type plasminogen activator (tPA) and aging, particularly in the context of Alzheimer’s disease. Like a determined investigator, they examined the links between tPA plasma concentration and cognition, brain structure, brain function, and amyloid burden in a diverse group of participants. This investigation revealed that as age increases, so does the concentration of tPA in the blood, with males having higher levels than females. Interestingly, among cognitively unimpaired adults and individuals with Alzheimer’s disease, tPA did not differ significantly. However, in cognitively unimpaired adults, higher tPA levels were associated with reduced global brain volume. Surprisingly, no connection was found between tPA levels and brain metabolism or amyloid deposition. Instead, tPA changes seemed linked to alterations in blood pressure, glycemia, and body mass index. While these findings shed light on the complex relationship between tPA and aging-related neuronal alterations, there is still much to unravel about this fascinating molecular protagonist! Dive into the original research for a deeper understanding.
Tissue-type plasminogen activator (tPA) is a protease known for its fibrinolytic action but is also involved in physiological and pathophysiological aging processes; including amyloid elimination and synaptic plasticity. The aim of the study was to investigate the role of tPA in cognitive and brain aging. Therefore, we assessed the links between tPA plasma concentration and cognition, structural MRI, FDG-PET and Flobetapir-PET neuroimaging in 155 cognitively unimpaired adults (CUA, aged 20-85 years old) and 32 patients with Alzheimer’s disease (ALZ). A positive correlation was found between tPA and age in CUA (p < 0.001), with males showing higher tPA than females (p = 0.05). No significant difference was found between ALZ patients and cognitively unimpaired elders (CUE). Plasma tPA in CUA negatively correlated with global brain volume. No correlation was found with brain FDG metabolism or amyloid deposition. Age-related tPA changes were associated to changes in blood pressure, glycemia and body mass index. Within the ALZ patients, tPA didn’t correlate with any cognitive or neuroimaging measures, but only with physiological measures. Altogether our study suggests that increased tPA plasma concentration with age is related to neuronal alterations and cardiovascular risk factors.
Dr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering Self-Enhancement Science for the Success of Society. With a keen interest in exploring the untapped potential of the human mind, Dr. Lowemann has dedicated his career to pushing the boundaries of human capabilities and understanding.
Armed with a Master of Science degree and a Ph.D. in his field, Dr. Lowemann has consistently been at the forefront of research and innovation, delving into ways to optimize human performance, cognition, and overall well-being. His work at the Institute revolves around a profound commitment to harnessing cutting-edge science and technology to help individuals lead more fulfilling and intelligent lives.
Dr. Lowemann’s influence extends to the educational platform BetterSmarter.me, where he shares his insights, findings, and personal development strategies with a broader audience. His ongoing mission is shaping the way we perceive and leverage the vast capacities of the human mind, offering invaluable contributions to society’s overall success and collective well-being.
